Ads
related to: drupal 9 vulnerabilities for prostate cancer treatment abiraterone
Search results
Results From The WOW.Com Content Network
Niraparib/abiraterone acetate, sold under the brand name Akeega, is a fixed-dose combination anti-cancer medication used for the treatment of prostate cancer. [2] It contains niraparib , a poly (ADP-ribose) polymerase (PARP) inhibitor (antineoplastic agent), and abiraterone acetate , a CYP17 inhibitor (hormone antagonist).
Abiraterone acetate is used in combination with prednisone, a corticosteroid, as a treatment for mCRPC (previously called hormone-resistant or hormone-refractory prostate cancer). [2] [6] [5] [4] This is a form of prostate cancer that is not responding to first-line androgen deprivation therapy or treatment with androgen receptor antagonists.
Δ 4-Abiraterone (D4A; code name CB-7627), also known as 17-(3-pyridyl)androsta-4,16-dien-3-one, is a steroidogenesis inhibitor and active metabolite of abiraterone acetate, a drug which is used in the treatment of prostate cancer and is itself a prodrug of abiraterone (another active metabolite of abiraterone acetate). [1]
Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...
Galeterone (developmental code names TOK-001, VN/124-1) is a steroidal antiandrogen which was under development by Tokai Pharmaceuticals for the treatment of prostate cancer. [1] It possesses a unique triple mechanism of action , acting as an androgen receptor antagonist , androgen receptor down regulator, [ 2 ] and CYP17A1 inhibitor , [ 3 ...
According to the charity Prostate Cancer UK, 144 men are diagnosed across the country each day – more than 52,000 per year. Rider’s former BBC colleague Bill Turnbull died in August 2022 ...
Ads
related to: drupal 9 vulnerabilities for prostate cancer treatment abiraterone